What happened with NEPH today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Nephros Inc. supplies filters that hospitals and other healthcare facilities use to control waterborne contaminants at water outlets and equipment, and to purify water and bicarbonate concentrate for dialysis. Its medical filters physically trap microorganisms; its ultrafilters also retain viruses and endotoxins. It also sells commercial filters that improve water taste and odor and reduce contaminants and buildup in beverage dispensers, coffee machines and ice makers.
Healthcare distributors buy and resell its medical filters, while Nephros also sells directly to hospitals and dialysis customers. Commercial sales likewise use direct sales and distribution partners. Customers reorder filters as scheduled replacements become due. The company also supplies filters for urgent water-quality problems, including outbreaks, but these orders are generally non-recurring and depend on when such events occur. Product sales provide nearly all revenue, and a few customers account for a substantial share.
Nephros does not manufacture its medical filtration products, though it makes some commercial products. It depends on Medica S.p.A. as the sole supplier of proprietary filter material for several products. Its agreement with Medica ties exclusive sales rights in the defined territory to minimum purchase commitments; failure to meet them can give Medica a termination right. Its U.S.-marketed medical filters are FDA-cleared for their intended uses, and new products may need regulatory clearance before they can be sold.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Nephros depends on repeat medical-filter orders and emergency water-quality deployments, with Cytiva a competitor to watch and Medica S.p.A. its exclusive manufacturing partner.
Pentair competes with Nephros to sell commercial customers filters that improve water quality, but its broader pump and pool businesses make its overall results a poor guide to Nephros’s medical-filter demand. Watch Pentair’s commercial filtration business rather than its pump or pool sales.
Pentair plc earningsPNR
Pentair’s report will show how demand for water-quality filters is changing among commercial customers, a market where it competes with Nephros.
Look at Pentair’s commercial filtration sales and demand commentary separately from its pump and pool businesses. Steady or rising filtration sales would suggest demand remains in the water-quality market where the companies compete; a decline there, even if pumps or pools are strong, would point to a tougher commercial-filter market for Nephros. This informs the commercial business, not Nephros’s own results or demand for its medical filters.
Nephros Inc. earningsThis company
Nephros’s report will show whether hospitals, dialysis settings and other customers keep reordering its filters, and whether cost pressure is eating into the sales gains.
Read product revenue growth alongside gross margin, and note whether Nephros attributes growth to routine reorders and new active sites or to emergency orders. Growth led by routine reorders and new sites with a steady margin would show that everyday filter demand is expanding without costs absorbing the gains; growth relying mainly on emergency orders, or a falling margin, would point to less predictable demand or cost pressure such as tariffs squeezing profit. That tells readers whether Nephros’s growth rests on repeat customer demand.
